AI Article Synopsis

  • The liver's parenchyma's structure involves specific interactions between hepatocytes and their supporting biomatrix.
  • A peptide called Hep105, found in rat hepatocytes and the liver biomatrix, is identified as a component of dipeptidyl peptidase IV (DPPIV).
  • Research shows that Hep105 and another peptide, Hep150, are structurally related, with Hep150 displaying DPPIV activity, while Hep105 is linked to the enzyme's active site.

Article Abstract

The histotypic organization of liver parenchyma involves specific intercellular contacts and interaction of hepatocytes with supporting biomatrix. Evidence from this laboratory identified a peptide (Hep105, apparent Mr 105 000) that is shared by the plasma membrane of rat hepatocytes and rat liver biomatrix. This report identifies Hep105 as a peptide component of dipeptidyl peptidase IV (DPPIV; EC 3.4.14.-). A monoclonal antibody (MAb 236.3) was shown to immunoprecipitate DPPIV from non-ionic detergent extracts of surface-labeled 125I hepatocytes. The immunoprecipitate contained two 125I-labeled peptides: Hep105 and a peptide of apparent Mr 150000 (Hep150). Proteolysis of 125I-labeled Hep105 and Hep150 by Staphylococcus aureus V8 protease yielded essentially identical patterns of 125I-labeled peptide degradation products, indicating that Hep105 and Hep150 are structurally related. Only Hep150 exhibited DPPIV activity on transblot analysis, an observation that is consistent with the interpretation that it is the monomeric form of the enzyme. Heating (100 degrees C, 5 min) of purified Hep150 in the presence of sodium dodecylsulfate (SDS) resulted in its conversion to Hep105 and the disappearance of any demonstrable enzymatic activity. 3H-labeled diisopropyl fluorophosphate was incorporated into Hep105, indicating that Hep105 contains the active site for DPPIV. Purified rat liver biomatrix was shown to possess significant DPPIV activity. Taken together, these data indicate that Hep105 s a peptide component of DPPIV.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0014-4827(85)90474-4DOI Listing

Publication Analysis

Top Keywords

liver biomatrix
12
hep105 peptide
12
hep105
9
dipeptidyl peptidase
8
shared plasma
8
plasma membrane
8
rat liver
8
peptide component
8
hep105 hep150
8
indicating hep105
8

Similar Publications

Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices.

J Chromatogr B Analyt Technol Biomed Life Sci

January 2025

Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pharmacy, Uppsala University, Uppsala, Sweden. Electronic address:

Article Synopsis
  • * A validated ultra-performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS) method was developed to accurately measure DNDI-6148 levels in various biological samples, following international guidelines on bioanalytical methods.
  • * The study found that collagenase A-based enzymatic homogenization extracted DNDI-6148 2.9 times more effectively from mouse skin compared to traditional methods, with consistent accuracy and recovery rates across different biomatrices
View Article and Find Full Text PDF

Hypoxia is one of the main hallmarks of hepatocellular carcinoma (HCC) resulting from improper oxygenation and insufficient nourishment of the HCC microenvironment. The effect of hypoxia is mediated by hypoxia-inducible factor-1A (HIF-1A) via targeting various downstream pathways, including glycolysis, angiogenesis, and survival signaling. However, HCC cell lines in a 2-dimensional (2D) setting do not resemble the metabolic signature of HCC.

View Article and Find Full Text PDF

Decellularized liver scaffolds for constructing drug-metabolically functional human liver models.

Bioact Mater

January 2025

Hepato-pancreato-biliary Center, Clinical Translational Science Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 102218, China.

The creation of human liver models has long been a critical objective in academic, clinical, and pharmaceutical research, particularly for drug development, where accurate evaluation of hepatic metabolic dynamics is crucial. We have developed a bioengineered, perfused, organ-level human liver model that accurately replicates key liver functions, including metabolic activities, and protein synthesis, thus addressing some of the limitations associated with traditional liver monolayers, organoids, and matrix-embedded liver cells. Our approach utilizes liver-specific biomatrix scaffolds, prepared using an innovative protocol and fortified with matrix components that facilitate cellular interactions.

View Article and Find Full Text PDF

Small Molecule-Mediated Stage-Specific Reprogramming of MSCs to Hepatocyte-Like Cells and Hepatic Tissue for Liver Injury Treatment.

Stem Cell Rev Rep

November 2024

Stem Cell and Molecular Biology, Laboratory, Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, 600036, India.

Background: Derivation of hepatocytes from stem cells has been established through various protocols involving growth factor (GF) and small molecule (SM) agents, among others. However, mesenchymal stem cell-based derivation of hepatocytes still remains expensive due to the use of a cocktail of growth factors, and a long duration of differentiation is needed, thus limiting its potential clinical application.

Methods: In this study, we developed a chemically defined differentiation strategy that is exclusively based on SM and takes 14 days, while the GF-based protocol requires 23-28 days.

View Article and Find Full Text PDF
Article Synopsis
  • Breath analysis has a long history in diagnosing diseases, but volatile organic compounds (VOCs) haven't been fully validated as biomarkers for specific illnesses yet.
  • This review focuses on the potential of VOC breath tests for diagnosing non-cancerous diseases, specifically precancerous conditions like GERD and Barrett's esophagus, inflammatory bowel diseases, and chronic liver diseases.
  • The analysis is based on 24 studies, discussing various factors such as analytical platforms and diagnostic parameters, and emphasizes the need for refined research methods to enhance the use of breath tests as non-invasive diagnostic tools.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!